Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has earned an average rating of “Hold” from the fourteen brokerages that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $18.06.
ZYNE has been the subject of several recent analyst reports. HC Wainwright set a $23.00 price objective on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, March 6th. Oppenheimer reaffirmed a “hold” rating on shares of Zynerba Pharmaceuticals in a research note on Tuesday, November 14th. Zacks Investment Research lowered shares of Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 18th. Cantor Fitzgerald initiated coverage on shares of Zynerba Pharmaceuticals in a research note on Monday, March 5th. They set a “buy” rating and a $17.00 target price for the company. Finally, Canaccord Genuity set a $18.00 target price on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, December 4th.
In related news, major shareholder Michael Rapp bought 15,000 shares of the stock in a transaction on Tuesday, January 2nd. The stock was bought at an average price of $12.99 per share, with a total value of $194,850.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 9.91% of the company’s stock.
Zynerba Pharmaceuticals (NASDAQ ZYNE) traded down $0.40 during trading on Friday, reaching $10.13. 132,507 shares of the company traded hands, compared to its average volume of 337,392. Zynerba Pharmaceuticals has a 52-week low of $5.42 and a 52-week high of $25.95. The firm has a market capitalization of $123.88, a PE ratio of -4.00 and a beta of 5.06.
TRADEMARK VIOLATION WARNING: “Zynerba Pharmaceuticals Inc (ZYNE) Receives $17.69 Average PT from Analysts” was originally reported by Markets Daily and is owned by of Markets Daily. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.themarketsdaily.com/2018/03/13/zynerba-pharmaceuticals-inc-zyne-receives-17-69-average-pt-from-analysts.html.
Zynerba Pharmaceuticals Company Profile
Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.